Aspirin as an augmenting to Sertraline for treating major depressive disorder, a randomized double blind placebo controlled clinical tria
Phase 2
- Conditions
- Major Depressive Disorder.Depressive episode
- Registration Number
- IRCT2016082829556N1
- Lead Sponsor
- Vice chancellor for research of Kashan University of Medical Sciences and Health Servisces,Kashan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
patients with major depressive disorder according to DSM-VI, both gender, and aged between 40 and 80 years old, Consent to participate in the study by completing the informed consent form, Having risk factors for coronary heart disease or stroke. Exclusion criteria: Depression due to physical illness or drug use, A history of gastric ulcers and contraindications for taking aspirin, pregnant women, History of alcohol and substance abuse within 6 months prior to the beginning of the study, positive history of mania, mental retardation, psychosis, using another antidepressant within 4 weeks prior to starting ASA, Candidates for other treatments such as ECT for depression.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Depression. Timepoint: baseline,4 week, and8 week. Method of measurement: Beck Depression Inventory.
- Secondary Outcome Measures
Name Time Method